Organon is significantly broadening its dermatology presence through the acquisition of Dermavant, a Roivant Sciences subsidiary, for a deal potentially worth $1.2 billion. The centerpiece of this acquisition is Vtama (tapinarof) cream, a commercially available treatment for plaque psoriasis, with potential expansion into atopic dermatitis.
The agreement specifies an upfront payment of $175 million from Organon to Roivant, with the remaining amount tied to milestone achievements. A near-term milestone includes a possible $75 million payment contingent on FDA approval of Vtama for atopic dermatitis, expected in the fourth quarter of this year.
Vtama: A Novel Non-Steroidal Topical Treatment
Vtama distinguishes itself as a non-steroidal topical cream that modulates inflammation by blocking signaling proteins. Approved for plaque psoriasis in 2022, it offers an alternative to traditional topical steroids. Its mechanism of action suggests potential applications beyond psoriasis, particularly in atopic dermatitis, where it is currently under regulatory review for patients aged 2 and older.
While Vtama's sales reached $75.1 million in the fiscal year ending March 31, showing growth from $28 million in the previous year, the drug faces strong competition in the plaque psoriasis market. Leerink Partners previously adjusted its 2032 revenue forecast for Vtama from $1.4 billion to $407 million, citing physician and patient comfort with existing generic topical steroids and branded alternatives. However, analysts see significant potential in the atopic dermatitis indication, especially given the preference for non-steroidal options in pediatric patients.
Organon's Dermatology Strategy
Organon, which spun out of Merck in 2021, has a portfolio including women's health and off-patent drugs. Its current dermatology offerings include Diproson and Elocon, topical corticosteroids for conditions like eczema and psoriasis. These products, along with bone health and non-opioid pain medications, generated $782 million in revenue last year, primarily outside the U.S., representing approximately 12% of Organon's total revenue.
The acquisition of Dermavant grants Organon global rights to Vtama, excluding China and Japan. Organon CEO Kevin Ali emphasized the company's global infrastructure as crucial for realizing Vtama's commercial potential. Roivant CEO Matt Gline echoed this sentiment, highlighting Organon's market access capabilities and regulatory expertise.
Roivant's Evolving Business Model
Roivant, known for acquiring and developing shelved drug assets, previously obtained Vtama's rights from GSK in 2018. The sale of Dermavant reflects Roivant's strategic shift towards focusing on specialty drug candidates with blockbuster potential. This move follows the sale of Televant to Roche for $7.1 billion and the recent launch of Pulmovant, a subsidiary focused on pulmonary hypertension associated with interstitial lung disease.
